Real estate
“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.
The last several years have marked several attempts to stimulate life sciences startups to pick the Big Apple.
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
Regeneron continues to expand its presence in New York. Over the next six years, the company will invest approximately $1.8 billion to expand its Tarrytown facilities. The investment will support the addition of 1,000 new jobs.
Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.
Thermo Fisher Scientific continues to open new facilities that enable it to meet increasing manufacturing demands.
Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.
Agenus, an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech’s manufacturing facility in Vacaville, Cali.
PRESS RELEASES